Transdermal drug delivery system

Transdermal drug delivery systems (TDDS), particularly in the form of patches, have emerged as a major breakthrough in pharmaceutical science, enabling drugs to be administered directly through the skin in a non-invasive manner. These systems allow controlled and sustained drug release, leading to improved therapeutic efficiency. Unlike conventional oral route Skin, TDDS bypass first-pass metabolism and help maintain consistent plasma drug concentrations. Progress in this field has been driven by the development of innovative materials, novel polymers, advanced permeation enhancers, and smart delivery platforms. The incorporation of nanotechnology has broadened the applicability of TDDS, making it possible to deliver molecules that were previously unsuitable for transdermal administration. Deeper understanding of skin physiology and its barrier functions has facilitated the design of next-generation patches utilizing nanocarriers, microemulsions, and stimuli-responsive polymers. Additionally, approaches such as microneedle arrays, iontophoresis, and sonophoresis have significantly boosted drug permeation across the skin. Several marketed products highlight the practical success of these technologies, while ongoing research continues to refine delivery strategies and evaluation techniques. Overall, the evolution of TDDS has led to more effective, convenient, and patient-friendly therapeutic options, positioning them as a promising platform for addressing complex treatment challenges and catering to diverse healthcare needs in the future.

Primaquine phosphate, 8-[(4-amino-1-methyl butyl)amino]-6-metoxyquinoline phosphate, a synthetic compound with potent antimalarial activity and clinical use for treatment of relapses of Plasmodium vivax infections. The drug is usually oral administered for 7-14 consecutive days to achieve radical cure and is known to produce adverse side-effect including gastrointestinal distress, nausea and methaemoglobinemia with cyanosis.  In transdermal drug delivery system provide benefits over the oral administration. It is an alternative drug delivery system, in recent years, high patient acceptance in many clinical conditions and the advantages of delivering drugs across the skin for systemic circulation.  Fabrication and Evaluation of matrix type Transdermal Patches of Primaquine Phosphate with different ratio of eudragit-L100 and S-100 combination by the solvent evaporation technique. All the patches have been evaluated for their Physiochemical properties was studied by infrared Spectroscopy. Formulation F1 was found best among the all formulation. Hence F1 formulation was used to incorporate penetration enhancer labrafac™ PD, labrefil® 1944CS and lauroglucol™ FCC. By using this three penetration enhancer nine formulation L1 to L9 was fabricated to increasing volume of 0.5ml, 1.0ml, 1.5 ml. All the formulation was tested for thickness, weight variation, folding endurance, surface pH, moisture content and %drug content. L6 was showing maximum drug content and folding endurance. The in-vitro release study was carried out with Shimadzu HPLC system. L6 formulation showed the best release.

Release of drugs via the skin has been always a challenging part for research due to obstacle properties shown by the outermost layer of skin stratum corneum. In the previous two decades, the transdermal drug delivery system has turn into a established technology that offers important clinical repayment over additional dosage forms. Because transdermal drug delivery offers controlled as well as programmed rate of release of the drug into the patient, it is capable to maintain steady state blood concentration. It’s a advantageous form of drug delivery because of the apparent advantages e.g. suitable and pain-free self-administration for patients, prevention of hepatic first-pass metabolism and the GI tract for poorly bioavailable drugs than other routes of deliverance.Thepresent article reviews the choice of drug candidates and polymers, advantages, disadvantages of formulation, design and the methods of evaluation, augmentation techniques based on drug/vehicle optimization such as selection of drug, prodrugs and ion pairs, supersaturated drug solutions, vesicles, liposomes, particles and complexations. This review also emphases on the recent innovations in TDDS, which be able to used for the research and improvement of pharmaceutical dosage form intended for transdermal drug delivery.